FDA Clears Way for Trials of FOR46 in Late-stage Multiple Myeloma, Prostate Cancer
The U.S. Food and Drug Administration has allowed Fortis Therapeutics’ antibody-drug conjugate FOR46 to begin testing in a Phase 1 clinical trial as a…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved Bristol-Myers Squibb‘s Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, as a treatment…
Darzalex Add-on Delays Disease Progression or Death in Newly Diagnosed Multiple Myeloma, Phase 3 Trial Shows
Treatment with Darzalex (daratumumab) plus standard Revlimid (lenalidomide) and dexamethasone significantly delays the time to disease progression or death in newly diagnosed multiple myeloma…
Myeloma Crowd Launches Online Tool to Help Patients Find Treatment Options, Contribute to Research
Myeloma Crowd has launched an online tool called HealthTree, aimed at helping patients with multiple myeloma find the most appropriate therapies for their condition,…
New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study
A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma…
Trip to Mount Everest’s Base Benefits MMRF-funded Multiple Myeloma Research
During a strenuous but spectacular hike, a team including four patients is traversing Nepal’s Khumbu region, encountering some of the world’s tallest mountains, and experiencing…
